Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer
Authors
Rocha, P.Rodrigo, M.
Moliner, L.
Rios-Hoyo, A.
Masfarre, L.
Navarro-Gorro, N.
Menendez, S.
Taus, A.
Rodriguez, A.
Aguilo, R.
Belda, J.
Del Rey-Vergara, R.
Galindo, M.
Comerma, L.
Arriola, E.
Issue Date
2022
Metadata
Show full item recordCitation
Rocha P, Rodrigo M, Moliner L, Rios-Hoyo A, Masfarre L, Navarro-Gorro N, et al. Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer. Annals of Oncology. 2022;33:S75-S.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.02.101Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.02.101Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.02.101